Price movement over the last 24 hours
ADMA Biologics Inc vs Progressive Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Progressive Corp trades at $233.46 (market cap $136.47B). The key difference: Progressive Corp is far larger — about 64.1× ADMA Biologics Inc's market cap, and Progressive Corp pays a 5.93% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PGR | |
|---|---|---|
Market Cap | $2.13B | $136.47B |
Sector | Health | Financials |
52-Week High | $20.38 | $252.68 |
52-Week Low | $7.60 | $190.40 |
Enterprise Value | $2.20B | $144.69B |
Dividend Yield | — | 5.93% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Progressive (PGR) trades at $234.40, up 0.94% with a bullish technical signal and strong fundamentals. Recent earnings beat expectations with Q1 2026 EPS of $4.96 versus $4.85 estimate, continuing a trend of operational strength. Revenue grew to $87.64B in 2025 with net income margin at 12.93%, while analyst consensus price target is $235.67. The stock shows resilience with positive media coverage highlighting earnings growth and leadership changes.
Outlook remains positive driven by earnings momentum and scale advantages in auto insurance. Key risks include competitive pressures and macroeconomic sensitivity. Institutional sentiment is mixed with 41.46% buy ratings, but the stock's valuation at P/E 11.78 offers room for upside if earnings trends persist.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →